Netapp, Inc.

Leland Stanford Junior University

Riboscience LLC

Network Appliance, Inc.

F. Hoffmann-la Roche Ag

European Molecular Biology Laboratory

Savira Pharmaceuticals Gmbh

Roche Palo Alto LLC

University of California

Other

Mark Smith

Klaus G Klumpp

Ananthan Subramanian

Abhijeet Prakash Gole

Helmut Heinrich Buschmann

Sung-Sau So

Ram Kesavan

Matthew Fontaine Curtis-Maury

Stephen Cusack

Norbert Handler

Andrea Wolkerstorfer

Oliver Szolar

Ronald Charles Hawley

Jeffrey S Glenn

Kevan M Shokat

Edgar George Engleman

Achyutharao Sidduri

Vinay Devadas

Abdul Basit

Ingrid Choong

Gaurav Banga

Nitin Muppalaneni

Michael A Gelman

Khoa Dinh Nguyen

Sourav Sen

Brandon Tavshanjian

Daniel Wang-Woei Ting

Samuel D Banister

David Bernard Smith

Zachary Kevin Sweeney

Zhuming Zhang

Mark Muhlestein

Michael Lee Federwisch

Ravikanth Dronamraju

Keshab Sarma

Joseph Armstrong Martin

Naresh M Patel

Kelsey Erin Shaw

Volker Boehnert

Lingyin Li

Jacqueline Ann Carozza

Robert M English

Rajesh Sundaram

Jennifer R Cochran

Counde O'Yang

Francisco Xavier Talamas

Bruno Giethlen

Todd Richard Elworthy

Jing Zhang

Joan Heather Hogg

Christophe Morice

Henk J Bots

Joshua Kennedy-Smith

Raghu Mallena

Edward A Pham

Brian Naylor

Nicholas Cox

Koling Chang

Jeffrey Wu

James R Kintzing

Kaustabh Basu

Stephen Stabler

Thibault Sauvaitre

Mike Federwisch

Yoshihito David Saito

SushilKumar Gangadharan

Dirk Classen-Houben

Thierry Langer

Céline Simon

Céline Michaut-simon

Laurence Jung

Céline Michaut-Simon

Thibault SAUVAÎTRE

Compounds and methods are provided for inhibiting a PI4-kinase. Methods of treating a pathogen infection and methods of treating cancer are also provided. The PI4-kinase inhibitor can be a compound that is a 5-aryl or heteroaryl-thiazole, e.g., as described herein. In certain embodiments, the PI4-kinase inhibitor is a substituted 2-amino-5-phenylthiazole or substituted 2-amino-5-pyridylthiazole compound. In some embodiments, the compounds have broad spectrum anti-infective activity against a variety of infective diseases, where the diseases are caused by pathogens containing a basic amino acid PIP-2 pincer (BAAPP) domain that interacts with phosphatidylinositol 4,5-bisphosphate (PIP-2) to mediate pathogen replication. Also provided are methods of treating a subject for cancer using a PI4-kinase inhibitor. Aspects of the methods include inhibiting PI4-kinase in a cancer cell to reduce cellular proliferation.

PI4-kinase inhibitors and methods of using the same

Methods and systems for a storage environment are provided. One method includes splitting storage of a plurality of zoned solid-state drives (ZNS SSDs) into a plurality of physical zones (PZones) across a plurality of independent media units of each ZNS SSD, the PZones visible to a first tier RAID (redundant array of independent disks) layer; generating a plurality of RAID zones (RZones), each RZone having a plurality of PZones; presenting one or more RZones to a second tier RAID layer by the first tier RAID layer for processing read and write requests using the plurality of ZNS SSDs; and utilizing, by the first tier RAID layer, a parity PZone at each ZNS SSD for storing parity information corresponding to data written in one or more PZone corresponding to a RZone presented to the second tier RAID layer and storing the parity information in a single parity ZNS SSD.

Methods and systems for raid protection in zoned solid-state drives

Techniques are provided for implementing a persistent memory storage tier to manage persistent memory of a node. The persistent memory is managed by the persistent memory storage tier at a higher level within a storage operating system storage stack than a level at which a storage file system of the node is managed. The persistent memory storage tier intercepts an operation targeting the storage file system. The persistent memory storage tier retargets the operation from targeting the storage file system to targeting the persistent memory. The operation is transmitted to the persistent memory.

Persistent memory architecture

A genus of compounds encompassed by formula (III) and their use is disclosed: The compounds activate Ppargc1a and, as a consequence, are useful for treating a variety of neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS), Alzheimer's disease, Parkinson's disease, Huntington's disease, frontotemporal degeneration, dementia with Lewy bodies, motor neuron diseases, and a demyelinating disease.

2-arylbenzimidazoles as Ppargc1a activators for treating neurodegenerative diseases

Techniques are provided for compacting indirect blocks. For example, an object is represented as a structure including data blocks within which data of the object is stored and indirect blocks including block numbers of where the data blocks are located in storage. Block numbers within a set of indirect blocks are compacted into a compacted indirect block including a base block number, a count of additional block numbers after the base block number in the compacted indirect block, and a pattern of the block numbers in the compacted indirect block. The compacted indirect block is stored into memory for processing access operations to the object. Storing compacted indirect blocks into memory allows for more block numbers to be stored within memory.

File system format for persistent memory

Compounds and methods are provided for the treatment of pathogen infections. In some embodiments, the anti-infective compounds have broad spectrum activity against a variety of infective diseases, where the diseases are caused by pathogens containing a basic amino acid PIP-2 pincer (BAAPP) domain that interacts with phosphatidylinositol 4,5-bisphosphate (PIP-2) to mediate pathogen replication. Also provided are methods of inhibiting a PI4-kinase and methods of inhibiting viral infection. In some embodiments, the compound is a PI4-kinase inhibiting compound that is a 5-aryl-thiazole or a 5-heteroaryl-thiazole. The subject compounds may be formulated or provided to a subject in combination with a second anti-infective agent, e.g. interferon, ribavirin, and the like.

PI-kinase inhibitors with anti-infective activity

Compounds, compositions and methods are provided for the inhibition of ENPP1. Aspects of the subject methods include contacting a sample with a ENPP1 inhibitor to inhibit cGAMP hydrolysis activity of ENPP1. In some cases, the ENPP1 inhibitor is cell impermeable. Also provided are compositions and methods for treating cancer. Aspects of the methods include administering to a subject a therapeutically effective amount of a ENPP1 inhibitor to treat the subject for cancer. In certain cases, the cancer is a solid tumor cancer. Also provided are methods of administering radiation therapy to a subject either before or after administering an ENPP1 inhibitor. The radiation therapy can be administered at a dosage and/or frequency effective to reduce radiation damage to the subject. In certain cases, the method is performed in combination with a chemotherapeutic agent, or a checkpoint inhibitor, or both.

ENPP1 inhibitors and their use for the treatment of cancer

Techniques are provided for implementing a file system format for persistent memory. A node, with persistent memory, receives an operation associated with a file identifier and file system instance information. A list of file system info objects are evaluated to identify a file system info object matching the file system instance information. An inofile, identified by the file system info object as being associated with inodes of files within an instance of the file system targeted by the operation, is traversed to identify an inode matching the file identifier. If the inode has an indicator that the file is tiered into the persistent memory, then the inode it utilized to facilitate execution of the operation upon the persistent memory. Otherwise, the operation is routed to a storage file system tier for execution by a storage file system upon storage associated with the node.

Cytidine nucleoside analogues of Formula I, wherein the variables are as described herein, in combination with uridine nucleoside analogues of Formula II, wherein the variables are as described herein, produce a synergistic effect on the inhibition of HCV polymerase.

4'-fluoro-2&#x2032;-methyl substituted nucleoside derivatives as inhibitors of HCV RNA replication

The compound 2-(4-tert-Butylphenyl)-1H-benzo[d]imidazol-5-ol: and its use are disclosed. The compound activates Ppargc1a and, as a consequence, is useful for treating neuroinflammation and for treating a variety of neurodegenerative diseases.

Growing community of inventors

San Francisco, CA, United States of America

Mark Smith